Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| treatment group | Experimental | transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) |
|
| control group | No Intervention | no neo-adjuvant treatment before operation |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TAI | Procedure | transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) |
|
| Measure | Description | Time Frame |
|---|---|---|
| OS | overall survival | From date of randomization until the date of death from any cause, assessed up to 60 months |
| Measure | Description | Time Frame |
|---|---|---|
| RFS | recurrence-free survival | From date of randomization until the date of recurrence, assessed up to 60 months |
| recurrence rate | recurrence rate |
Not provided
Inclusion Criteria:
older than 18 years old and younger than 75 years;
ECOG PS≤1;
proven hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria;
not previous treated for tumor;
the tumor was diagnosed as BCLC stage A/B and beyond Milan criteria;
no distant metastasis;
the lab test could meet:
sign up consent.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shaohua Li, MD | Contact | +8615088064187 | lishaoh@sysucc.org.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SUN YAT-SEN University Cancer Center | Recruiting | Guangzhou | Guangdong | 510060 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 year, 2 year, 3 year, 5 year after surgery |
| PFS | progression free survival | From date of randomization until the date of progression, assessed up to 60 months |
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |
Not provided
Not provided